Trials / Completed
CompletedNCT01161173
An Observational Study of Tarceva (Erlotinib) in Routine Daily Clinical Practice as Second Line Treatment in Patients With Non-small Cell Lung Cancer
A Non-interventional Study to Follow and Evaluate Patients With Advanced NSCLC Who Are Treated in Second Line Setting With Tarceva (Erlotinib) in a "Real Life" Clinical Setting
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 347 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This observational study will evaluate the safety and efficacy of Tarceva (erlotinib) in routine clinical practice as second-line treatment in patients with recurrent or metastatic non-small dell lung cancer (NSCLC). Data will be collected from patients who have received 1 course of standard systemic chemotherapy, experienced disease progression, and who are receiveingTarceva in a second-line setting. Patients will also be followed through third-line treatment if there is disease progression on Tarceva therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Erlotinib | Erlotinib was provided in the retail versions of the product. |
Timeline
- Start date
- 2008-04-01
- Primary completion
- 2012-08-01
- Completion
- 2012-08-01
- First posted
- 2010-07-13
- Last updated
- 2016-03-28
- Results posted
- 2016-03-28
Locations
36 sites across 2 countries: Belgium, Luxembourg
Source: ClinicalTrials.gov record NCT01161173. Inclusion in this directory is not an endorsement.